1,125.00p-5.00 (-0.44%)16 Apr 2025, 13:30
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

4Basebio PLC Fundamentals

Company Name4Basebio PLCLast Updated2025-04-16
IndustryBiotechnologySectorHealthcare
Shares in Issue15.472 mMarket Cap£174.06 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.62EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio-2.2859Cash Equity Ratio-0.5209
Quick Ratio1.5346Current Ratio2.73
Price To Book Value0ROCE0

4Basebio PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

4Basebio PLC Company Financials

Assets20232022
Tangible Assets£4.20 m£3.63 m
Intangible Assets£2.67 m£2.12 m
Investments00
Total Fixed Assets£6.90 m£5.79 m
Stocks£332,000.00£133,000.00
Debtors£107,000.00£54,000.00
Cash & Equivalents£3.07 m£4.35 m
Other Assets00
Total Assets£11.92 m£11.69 m
Liabilities20232022
Creditors within 1 year£2.28 m£1.52 m
Creditors after 1 year£10.14 m£3.05 m
Other Liabilities00
Total Liabilities£12.41 m£4.57 m
Net assets-£492,000.00£7.12 m
Equity20232022
Called up share capital£11.13 m£11.13 m
Share Premium£706,000.00£706,000.00
Profit / Loss-£8.35 m-£5.93 m
Other Equity-£492,000.00£7.12 m
Preference & Minorities00
Total Capital Employed-£492,000.00£7.12 m
Ratios20232022
Debt Ratio0£0.29
Debt-to-Equity0£0.41
Assets / Equity-2.2859-2.2859
Cash / Equity-0.5209-0.5209
EPS-£0.62-£0.42
Cash Flow20232022
Cash from operating activities-£6.18 m-£4.70 m
Cashflow before financing£247,000.00-£3.46 m
Increase in Cash-£1.24 m-£5.40 m
Income20232022
Turnover£506,000.00£268,000.00
Cost of sales£166,000.00£29,000.00
Gross Profit£340,000.00£239,000.00
Operating Profit-£8.05 m-£5.84 m
Pre-Tax profit-£8.35 m-£5.93 m

4Basebio PLC Company Background

SectorHealthcare
Activities4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.
Latest Interim Date27 Sep 2024
Latest Fiscal Year End Date5 Jun 2024

4Basebio PLC Directors

AppointedNamePosition
2024-06-28Mr. Timothy Paul McCarthyNon-Executive Director,Chairman
2024-09-21Dr. Joseph M. FernandezNon-Executive Director
2024-06-28Mr. Hansjorg PlaggemarsNon-Executive Director
2025-04-04Dr. Heikki Lanckriet, PhDExecutive Director,Chief Executive Officer
2024-09-21Mr. David John RothExecutive Director,Chief Financial Officer and Company Secretary
2025-03-03Dr. Amy Jo WalkerExecutive Director,Chief Operating Officer

4Basebio PLC Contact Details

Company Name4basebio PLC
Address25 Norman Way, Over, Cambridge, CB24 5QE
Telephone+44 1223967943
Websitehttps://www.4basebio.com

4Basebio PLC Advisors